PET/CT Scans | NYU Langone Health
NYU Langone offers PET/CT scans to diagnose illness, evaluate treatments, and assess the recurrence of many conditions, including cancer.
Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A Multi-Country Non-Interventional Prospective Cohort Study Among Patients with Human Growth Hormone (hGH) Treatments Under Routine Clinical Care
This study will explore how safe and effective hGH treatments are in the long term. This study is “non-interventional” because it collects information only.
Pharyngeal Exercise (Plus Protein) To Build Pharyngeal Muscular Reserve
The purpose of this study is to learn more about how exercise and protein supply affect muscles involved in swallowing. Many older adults experience disruptions to swallowing, which can have negative consequences on both health and quality-of-life. Participants will be offered $199 in compensation upon completion of each assessment visit, for a total of $597 upon study completion.
Phase 1 Clinical Trial of Innate Immunity Stimulation via TLR9 in Early AD (Part the Cloud)
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of study drug called CpG 1018 ISS to slow or prevent Alzheimer’s disease (AD) progression. Alzheimer’s disease is caused by a buildup of amyloid and tau proteins in the brain. CpG 1018 ISS may trigger an immune response to reduce amyloid protein from building up in the brain. This study has three dose levels and is for patients who have been diagnosed with either mild cognitive impairment (MCI) or mild Alzheimer’s disease dementia. CpG 1018 ISS is considered investigational because it is not Food and Drug Administration (FDA) approved for preventing AD progression.
Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients with Advanced Solid Tumors
This study is about a new medicine called ICVB-1042 (kills tumor cells) for people with advanced solid tumors. It has two parts: one where we figure out the right dose that has few side effects and is safe for patients to consume, and another where we see if it works in treating the advanced solid tumors. We'll test it on patients who've had cancer get worse even after trying other treatments. Patients will participate in the study for a few months. ICVB-1042 will be given through a vein on three different days out of a 7-day treatment period. The main goal is to make sure the medicine has few side effects and to find the best dose to use in future studies that will treat advanced solid tumors. We'll also check how the medicine moves in the body and if the body makes any "anti-drug" reactions.
Phase 1 First-In-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
This study is investigating a drug called AMG 305, which is designed to target specific cancer cells that have CDH3 and MSLN. This is a unique drug that brings T cells to tumors that express CDH3 and MSLN (commonly seen in non-small cell lung cancer, pancreatic cancer and colorectal cancer). The study wants to find out if AMG 305 is safe and effective for treating advanced or metastatic solid tumors. The study will be done in different stages. In the first stage, called "Dose Exploration," a small group of participants will receive different doses of the drug to see what dose works best in treating the tumors. The dose will be slowly increased until they find the highest dose that is safe. The participants will be closely watched to see how they respond to the treatment.Once they know the safe and effective dose, they will move on to the second stage, called "Dose Expansion." In this stage, more participants with different types of tumors will join the study. They will receive different doses and schedules of the drug to confirm its safety and effectiveness. They will also do extra tests to learn more about how the drug works.During the study, participants will get AMG 305 through short-term IV infusions. The dose may change based on how they react to it. Participants who benefit from the treatment may have the option to get it again later. But if they had to stop because of bad side effects, they won't be able to get it again.[The study has a careful plan and will use the information from each stage to make sure AMG 305 is safe and effective for treating solid tumors.
Phase 1/1b Multicenter Open-Label Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors
This study is looking at a medicine called RMC-9805 for adults with certain advanced cancers (that are KRASG12D-mutant). The study has two parts: one where they figure out the right dose of the medicine, and another where they test it more. They want to see if it has few side effects, how the body handles it, and if it helps shrink tumors. They'll look at people with different types of cancers, like lung, pancreas, and colorectal cancers. If the medicine seems safe, they might add more groups to the study to see how it workswith other cancer treatments.
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
A study called TNG462-C101 is being conducted to test a new medicine called TNG462 on patients with advanced or metastatic solid tumors who have a genetic alteration known as MTAP loss or MTAP deletion. The study has two parts: Phase 1 and Phase 2. In Phase 1, different doses through dose escalation (the process of gradually increasing the amount or strength of a medication given to a patient over time) of TNG462 will be given every day, and the positive effects and any side effects of TNG462 will be closely monitored. The dose will be increased slowly based on the results from previous patients. In Phase 2, the selected dose from Phase 1 will be tested on more patients in a dose expansion (when a selected dose of a medication, previously chosen in a dose-escalation phase, is further tested on a larger group of patients) phase to see if it works well. The study will also check how the body processes the medicine and how it affects the tumors. Before patients can join the study, they will be checked to see if they have certain genetic changes related to their tumors that may affect results. The study will collect samples and do tests to make sure the medicine is safe and accepted by patients. If patients have any side effects, their dose may be changed.
Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C
The purpose of the study is to determine and to evaluate the safety as well as efficacy of investigational treatment arms with or without pembrolizumab in participants with Stage III melanoma who are candidates for neoadjuvant therapy to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. We want to assess the safety and tolerability of investigational treatment combinations based on the proportion of participants with adverse events (AEs) and we want to to evaluate pathological complete response (pCR) rate as assessed by central review of the pathology results.
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumorsand is testing a novel epigenetic modifying strategy to restore tumor cell differentiation. The study will evaluate safety, tolerability, and pharmacokinetics of NUV-868, a BD-2 selective inhibitor of BRD4 as monotherapy and in combination with olaparib or enzalutamide and evaluate antitumor activity in advanced solid tumors.